CLPTCLPTHealthcare · Medical Devices

CLPT Stock Forecast: ClearPoint Neuro, Inc. Price Predictions for 2026-2027

Last close, 20 Nov 2026
$6.92
−5.40% on the day

The median 12-month analyst price target for ClearPoint Neuro, Inc. is $22. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 29 of 100 as at 21 Nov 2026 — in the lower half.

Market cap
$234.3M
Ticker Nerd rank
29/ 100
Median analyst target
$22
Analysts covering
2
Revenue$10.9M+18.1% y/y
Operating income−$10.2M
Net income−$11.3M
Free cash flow−$7.2M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−18.5%
1M
−26.8%
YTD
−49.5%
1Y
−48.8%
From 52W high
−64.4%
From 52W low
0.0%
$7
$19
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

One number for the whole business

Consensus tells you what everyone already believes. The model scores ClearPoint Neuro, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 21 Nov 2026
29/ 100

Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Revisions
86
Quality
50
Growth
45
Value
40
Momentum
20
Accruals
18
Volatility
16
Issuance
10

Revisions (86): Analysts have, on balance, been raising their forecasts.

Issuance (10): The company has been issuing shares or taking on financing, diluting existing holders.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

CLPT stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on CLPT, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$5$10$15$20$25Jan 26Apr 26Jul 26Oct 26CLPTHigh $25Median $22Low $18

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says2 analysts
2
Buy
0
Hold
0
Sell
$18
Low
$22
Median
$25
High
Recent analyst actionsNewest first
DateFirmActionRatingTarget
29 Oct 2026StifelMaintainsBuy$22 → $18
18 June 2026B. Riley SecuritiesMaintainsBuy$20 → $30
18 Mar 2026B. Riley SecuritiesMaintainsBuy—
5 Mar 2026B. Riley SecuritiesMaintainsBuy—
1 Aug 2025StifelMaintainsBuy—
25 Apr 2025B. Riley SecuritiesMaintainsBuy—
1 Apr 2025StifelMaintainsBuy—
28 Jan 2025B. Riley SecuritiesMaintainsBuy—
21 Jan 2025Lake StreetMaintainsBuy—
27 Aug 2024Lake StreetMaintainsBuy—
13 Mar 2024StifelReiteratesBuy—
24 Oct 2023StifelInitiatesBuy—
9 Aug 2023Lake StreetMaintainsBuy—
16 Feb 2023B. Riley SecuritiesReinstatesBuy$14
5 Apr 2022B. Riley SecuritiesReinstatesBuy$15
18 Mar 2021Lake StreetInitiatesBuy—
17 July 2020B. Riley SecuritiesInitiatesBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for CLPT.

Market Radar

This page is one stock. Monday covers all of them.

CLPT appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.

Free. Unsubscribe any time. Privacy

The AI build-out map
PDF
  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and servers

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Performance

CLPT vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 20 Nov 2026, ClearPoint Neuro, Inc. returned −48.8% against +6.9% for the S&P 500, dividends included.

CLPT vs S&P 500, last 12 monthsTotal return, rebased to 100
406080100120140Jan 26Apr 26Jul 26Oct 26CLPTS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

CLPT analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingThis fiscal year
Analysts raising
1
Analysts cutting
0
Fundamentals

Financials

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
—
Price / sales
5.2×

Cheaper than 21% of US stocks

Price / book
8.6×

Cheaper than 9% of US stocks

EV / EBITDA
—
Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
61.7%

Higher than 75% of US stocks

Operating margin
−66.6%

Higher than 17% of US stocks

Net margin
−79.4%

Higher than 7% of US stocks

Returns & dividend
Return on equity
−167.5%

Higher than 9% of US stocks

Return on assets
−21.9%

Higher than 18% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.

Statistics

Key statistics

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • ClearPoint Neuro, Inc. has a market value of $234.3M and an enterprise value of $261.8M.

  • Revenue in the twelve months to 30 June 2026: $42.3M. The latest quarter grew 18.1% year on year.

  • Net income over the same four quarters: −$34.6M, a −81.8% net margin.

  • Free cash flow in the twelve months to 30 June 2026: −$31.3M.

  • Shares outstanding: 30.5M.

  • ClearPoint Neuro, Inc. employs 172 people — $246K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 20 Nov 2026

Data provided by Twelve Data

Peers

CLPT and its peers

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelMedical Devices
CompanyMarket capTKN rank
CLPTClearPoint Neuro, Inc.$234.3M29
OFIXOrthofix Medical, Inc.$240.4M60
QSIQuantum-Si, Inc.$199.7M49
SSIISS Innovations International, Inc.$245.9M11
LABStandard BioTools, Inc.$246.1M41
ELMDElectromed, Inc.$191.7M89
RXSTRxSight, Inc.$185.0M54

Take a look at CLPT’s peer groups, ranked by the model: healthcare stocks.

Look up any of the roughly 4,300 stocks we score.

The rank is the raw material. Whether the rules would actually own ClearPoint Neuro, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

FAQ

Questions about CLPT

What is the CLPT stock price forecast for 2026-2027?

The median 12-month analyst price target for ClearPoint Neuro, Inc. is $22, with estimates ranging from $18 to $25. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is CLPT stock a buy right now?

Of the 2 analysts covering ClearPoint Neuro, Inc., 2 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks ClearPoint Neuro, Inc. 29 out of 100 across roughly 4,300 US stocks as at 21 Nov 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank CLPT?

As at 21 Nov 2026, ClearPoint Neuro, Inc. ranks 29 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Revisions (86 of 100).

Will CLPT stock go up?

No one can know that. What the data says: the median 12-month target from 2 analysts is $22, and Ticker Nerd's factor model ranks ClearPoint Neuro, Inc. 29 out of 100 as at 21 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the CLPT stock forecast for 2030?

No analyst covering ClearPoint Neuro, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for CLPT are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $18 to $25 over the next 12 months.

How has CLPT stock performed over the past year?

ClearPoint Neuro, Inc. returned -48.8% over the 12 months to 20 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.

What does ClearPoint Neuro, Inc. do?

ClearPoint Neuro Inc. is a medical technology company focused on precision navigation and delivery solutions for complex neurological procedures. The company develops and commercializes platforms used in minimally invasive brain and spine interventions, combining hardware, disposable instruments, and software that support surgical planning, targeting, and procedure monitoring.

Company

About ClearPoint Neuro, Inc.

ClearPoint Neuro Inc. is a medical technology company focused on precision navigation and delivery solutions for complex neurological procedures. The company develops and commercializes platforms used in minimally invasive brain and spine interventions, combining hardware, disposable instruments, and software that support surgical planning, targeting, and procedure monitoring. Its product portfolio includes MRI-guided navigation systems, laser therapy tools, and therapy-delivery components designed to help clinicians access hard-to-reach areas of the central nervous system with greater control. ClearPoint Neuro also provides enabling services for cell, gene, and drug delivery programs, supporting medical and research partners with preclinical and clinical development workflows. The company serves healthcare and research centers across multiple global regions, making it an important specialist in image-guided neurosurgical technology and therapeutic delivery.

CEO Mr. Joseph Michael Burnett · 172 employees · United States · https://www.clearpointneuro.com